Wegovy (semaglutide) injection and tablets
Wegovy and the Wegovy pill: side effects, coupon, cost and online care
Wegovy is Novo Nordisk’s brand of semaglutide for long-term weight management. It comes as a pen you inject once a week and as a tablet, the Wegovy pill, that you take once a day.1 With FitRx, a licensed provider reviews your health history online, decides whether Wegovy is appropriate and in which form, and follows you through each dose step.
- A U.S.-licensed provider reviews your intake, typically within 1 to 2 business days
- An insurance coordination team submits prior authorizations to commercial plans
- Monthly video or phone visits, with unlimited provider messaging in between
FitRx membership costs $39 the first month and $135 a month after that. Medication is billed separately. Prescribing is a provider’s decision, and not everyone qualifies.

What the trials found
In separate trials, adults lost an average of 14.9% on the Wegovy pen and 13.6% on the Wegovy pill
The pen. STEP 1 followed adults with obesity or overweight, and without diabetes, for 68 weeks. Average weight loss was 14.9% with the weekly 2.4 mg injection and 2.4% with placebo.2 Starting weight averaged about 232 pounds. On Wegovy, 83.5% of people lost at least 5% of their weight and 30.2% lost 20% or more.1
The pill. OASIS 4 tested the 25 mg daily tablet for 64 weeks. Average weight loss was 13.6% with the Wegovy pill and 2.4% with placebo, and 76.3% of the tablet group lost at least 5%.1
These were two trials, with different participants and different lengths. The two figures are not a head-to-head comparison, and they do not show that one form works better.
Two more results fill in the picture. In STEP UP, adults with obesity lost an average of 18.8% on a 7.2 mg weekly dose, 15.5% on 2.4 mg and 3.9% on placebo over 72 weeks.3 In the two-year STEP 5 trial, average loss at 104 weeks was 15.2% with semaglutide and 2.6% with placebo.4
All of these are averages: some people lost more, some less. Wegovy is approved for use with a reduced-calorie diet and more physical activity, not in place of them.
Brand-name Wegovy or compounded semaglutide: two routes through FitRx
Semaglutide is the active ingredient in Wegovy. If a FitRx provider decides it suits you, it can reach you by one of two routes. They are different products, and one cannot simply be swapped for the other.
FDA-approved
Brand-name Wegovy
Manufactured by Novo Nordisk and reviewed by the FDA for safety, effectiveness and quality. Taken as a weekly injection or a daily tablet.1
- The product tested in the STEP and OASIS 4 trials
- FitRx submits prior authorizations to commercial plans
- You pay the pharmacy: a copay with coverage, a cash price without
Not FDA-approved
Compounded semaglutide
Made for one patient’s prescription by a state-licensed compounding pharmacy. Through FitRx it starts at $151 a month with a 3-month supply, in addition to membership. Shipping is included.
- A 3-month supply ships as three vials in one box
- Not a generic of Wegovy or Ozempic, and never tested in their trials
- Prescribed only if a provider decides it is appropriate for you
What “not FDA-approved” means. Before a compounded drug is dispensed, the FDA has not checked its safety, its effectiveness or its quality. The agency says compounded drugs should only be used by patients whose medical needs cannot be met by an FDA-approved drug. It has also received reports of adverse events that may be related to dosing errors with compounded injectable semaglutide.5 Your provider will explain whether a compounded medication makes sense in your case.
The Wegovy pill versus the pen: a daily tablet or a weekly injection
The Wegovy pill is semaglutide in a tablet. It is approved for adults only: for weight management in people with obesity, or with overweight and at least one weight-related condition, and to lower cardiovascular risk in people with established cardiovascular disease and obesity or overweight. The pen’s label is wider. It also covers patients 12 and older with obesity, and adults with the liver disease MASH.1
| Feature | Wegovy pill | Wegovy pen |
|---|---|---|
| How often | Once a day | Once a week |
| How it is taken | Swallowed in the morning on an empty stomach | Injected under the skin |
| Dose steps | 30 days each on 1.5 mg, 4 mg and 9 mg, then 25 mg. | 4 weeks each on 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, then the maintenance dose. |
| Maintenance dose | 25 mg a day | 2.4 mg a week (recommended) or 1.7 mg. Up to 7.2 mg for some adults. |
| Average weight loss in its trial | 13.6% at 64 weeks (OASIS 4) | 14.9% at 68 weeks (STEP 1) |
| If you miss a dose | Skip it. Take the next tablet the following day. | Take it if the next dose is more than 2 days away. Otherwise skip it. |
| Self-pay price per month | $149 to $299, by dose | $349 for standard doses, $399 for 7.2 mg |
Dosing and trial results are from the Wegovy prescribing information.1 The trials were separate, so their results cannot be compared directly. Prices are Novo Nordisk’s self-pay prices as of November 18, 2026, and can change.6
How to take the Wegovy pill
Morning, empty stomach
Take your tablet in the morning, before you eat or drink anything.
Plain water only
Swallow the tablet whole with up to 4 ounces of plain water.
Wait 30 minutes
Leave at least 30 minutes before food, other drinks or other medicines taken by mouth.
The daily dose rises in steps: 1.5 mg on days 1 to 30, 4 mg on days 31 to 60, 9 mg on days 61 to 90, and 25 mg, the maintenance dose, from day 91. Take no more than one tablet a day. If you forget one, skip it and take the next one the following day.1
What the pill’s trial showed
In OASIS 4, people on 25 mg tablets lost an average of 13.6% of their body weight over 64 weeks, against 2.4% on placebo. On the tablet, 59.8% lost at least 10% (14.4% on placebo) and 47.0% lost at least 15% (5.5% on placebo).1
Switching between the pill and the pen
- Pen to pill: the first 25 mg tablet is taken one week after the last 2.4 mg injection.
- Pill to pen: the first 2.4 mg injection is given the day after the last 25 mg tablet.
Those are the label’s rules for the maintenance doses.1 A switch is a prescribing decision, so do not change forms on your own.
What the Wegovy pill costs
As of November 18, 2026, the self-pay price is $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg or 25 mg. A month is one bottle of 30 tablets. With commercial insurance that covers Wegovy, the savings offer can bring a bottle down to as little as $25 a month.6,7 Confirm current prices before you fill, and see Wegovy coupon and cost for the terms.
Daily tablet or weekly injection? That depends on your routine, your coverage and your health history, and it is a question to settle with your provider.
Getting Wegovy online: four steps from intake to first dose
Complete the online intake
You answer questions about your weight history, health conditions, current medicines and goals.
A provider reads it
A U.S.-licensed physician or nurse practitioner reviews it, typically within 1 to 2 business days, and decides whether medication is appropriate.
Prescription and coverage
If Wegovy is a fit, your provider prescribes it. If your commercial plan wants a prior authorization, FitRx files it. Most answers arrive in 2 to 14 business days.
Start low, stay in touch
Treatment begins at the lowest dose: 0.25 mg for the pen or 1.5 mg for the pill. Your provider manages each increase.
For weight management, Wegovy’s label covers adults with obesity (a BMI of 30 or higher) and adults with overweight (a BMI of 27 or higher) who have at least one weight-related condition.1 The BMI calculator will give you your number. FitRx treats adults 18 and older.
The label’s warnings shape that review. A family history of medullary thyroid cancer, past pancreatitis or gallbladder disease, diabetes medicines, pregnancy plans and upcoming surgery all matter. The provider makes the final call, and sometimes that call is a different medication or none at all.
What your FitRx membership covers
Wegovy’s label pairs it with a reduced-calorie diet and more physical activity, and the dose changes several times in the first months.1 Membership pays for the people who help with that.
A provider who knows your case
Review of your intake, a video or phone visit each month, and secure messaging with no limit.
A coach and a coordinator
A dedicated coach for daily habits, and a care coordinator for practical questions.
Insurance coordination
A team files your prior authorization for brand-name GLP-1s and can refile after a denial, up to three requests.
The price: $39 for your first month and $135 a month after that, billed monthly. Quarterly, semi-annual and annual plans cost less. HSA and FSA cards are accepted. You can cancel in the patient portal at any time. Memberships cannot be paused, and a prior authorization lasts only while membership is active.
Not in the price: your medication. You pay the pharmacy for brand-name Wegovy, at your plan’s copay or a cash price. FitRx does not sell it or set its price, and does not work with government insurance such as Medicare, Medicaid or TRICARE.
Wegovy side effects: common, serious and what changes at the highest dose
The most common Wegovy side effects involve the stomach and gut. The table shows how often adults reported each one in trials of the 2.4 mg injection.1
| Side effect | Wegovy 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 10% |
| Headache | 14% | 10% |
| Fatigue | 11% | 5% |
| Indigestion | 9% | 3% |
| Dizziness | 8% | 4% |
| Bloating | 7% | 5% |
| Belching | 7% | Under 1% |
| Low blood sugar (with type 2 diabetes) | 6% | 2% |
| Gas | 6% | 4% |
| Gastroenteritis | 6% | 4% |
| Acid reflux | 5% | 3% |
| Gastritis | 4% | 1% |
| Hair loss | 3% | 1% |
| Dysesthesia (altered skin sensation) | 2% | 1% |
Adults in trials of the 2.4 mg injection: 2,116 on Wegovy, 1,261 on placebo.1
Side effects at 7.2 mg
The Wegovy HD trial compared 7.2 mg with 2.4 mg and placebo. The clearest difference was dysesthesia, reported by 22% of people on 7.2 mg.1
| Side effect | 7.2 mg | 2.4 mg | Placebo |
|---|---|---|---|
| Nausea | 39% | 35% | 13% |
| Vomiting | 22% | 16% | 6% |
| Dysesthesia | 22% | 6% | 0% |
| Constipation | 20% | 19% | 8% |
| Abdominal pain | 12% | 9% | 7% |
| Fatigue | 11% | 9% | 5% |
| Headache | 9% | 8% | 7% |
| Dizziness | 6% | 5% | 1% |
| Hair loss | 6% | 3% | 1% |
The 7.2 mg trial: 1,311 people on 7.2 mg, 304 on 2.4 mg, 303 on placebo.1
Wegovy pill side effects
The pen and the pill share one label, and its warnings cover both. One figure is reported for each form: gallstones occurred in 2.5% of people on tablets (1% on placebo) and 1.6% on the injection (0.7% on placebo).1
Why Wegovy starts low
The pen steps up every four weeks, through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, and maintenance starts in week 17. If a step is hard on you, the label tells prescribers to consider delaying the next increase by 4 weeks, and 1.7 mg is an approved maintenance dose for adults. Tell your provider early.
Missed a pen dose? Take it as soon as you can if your next dose is more than 2 days (48 hours) away. Otherwise skip it. After 2 or more missed doses in a row, your prescriber may restart you at a lower dose.1
Vomiting and diarrhea drain fluid, which is how the kidney injury on the label happens. The medication guide says it is important to drink fluids when you have nausea, vomiting or diarrhea.1 If you cannot keep liquids down, contact your care team.
Serious risks and warning signs
- Thyroid C-cell tumors (the boxed warning). Report a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
- Pancreatitis. Severe stomach-area pain that will not go away, with or without vomiting, sometimes felt in the back.
- Gallbladder disease. Upper stomach pain, fever, yellowing of the skin or eyes, or clay-colored stools.
- Severe stomach reactions. Wegovy is not recommended with severe gastroparesis.
- Low blood sugar with insulin or a sulfonylurea, kidney injury from fluid loss, allergic reactions, a faster heart rate, and diabetic eye complications in people with type 2 diabetes.
- Aspiration during anesthesia. Tell the team you take Wegovy before general anesthesia or deep sedation.
What happens after you stop
STEP 1 participants were followed for a year after treatment ended. They had lost an average of 17.3% on semaglutide. A year after stopping, they had regained 11.6 percentage points, leaving a net loss of 5.6%.8 Plan any stop with your provider.
See the important safety information below and our GLP-1 side effects guide.
Wegovy coupon and Wegovy cost: the $25 offer, cash prices and Medicare
Novo Nordisk’s list price for Wegovy is $1,349.02 per package, whether that is the pen, the HD pen or the pill.6 What you pay depends on your coverage. These are Novo Nordisk’s published terms as of November 18, 2026.
| Your situation | What you could pay | The fine print |
|---|---|---|
| Commercial insurance that covers Wegovy | As little as $25 a month | The savings offer takes off no more than $100 a month. A month is one box of 4 pens or one bottle of 30 tablets. |
| Paying cash for the pen | $349 a month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg. $399 a month for Wegovy HD 7.2 mg. | New patients pay $199 a month for the first 2 monthly fills of 0.25 mg or 0.5 mg, through December 31, 2026. Needles are included. |
| Paying cash for the pill | $149 a month for 1.5 mg, $199 for 4 mg, $299 for 9 mg or 25 mg | A month is one bottle of 30 tablets. |
| Medicare Part D | $50 a month, if you qualify for the Medicare GLP-1 Bridge | Covers the Wegovy injection or tablet. FitRx cannot process it. |
| Medicaid, TRICARE or other government coverage | Depends on the program | Not eligible for the savings offer. |
Sources: Novo Nordisk’s NovoCare and Wegovy cost pages.6,7 Prices and terms change. Confirm them with Novo Nordisk or your pharmacy before you fill.
The Wegovy coupon and its cap
The Wegovy coupon is Novo Nordisk’s savings offer, and it is for people whose commercial insurance already covers Wegovy. It pays part of your copay, up to $100 a month, and that cap decides your price. For example, with a $125 copay you would pay $25. With a $300 copay the offer still covers $100, and you would pay $200. People with government coverage are excluded.6
Paying cash
The $199 introductory price lines up with the label’s schedule: the first four weeks are at 0.25 mg and the next four at 0.5 mg. From there the pen is $349 a month at every standard dose, and the price does not change with refill timing.6,7 GoodRx listed the same prices in November 2026. A coupon price is a cash price: it cannot be combined with insurance or the $25 offer, and it does not count toward a deductible.9 Our GoodRx Wegovy guide has the details.
Getting a commercial plan to cover Wegovy
Plans that cover Wegovy often want a prior authorization first. FitRx’s insurance coordination team submits it for members. Most decisions arrive in 2 to 14 business days, and after a denial the team can resubmit, up to three requests in all. The plan decides, and approval is never guaranteed. Our GLP-1 insurance checker explains the process.
Wegovy and Medicare
The Medicare GLP-1 Bridge is a short-term federal program running from July 1, 2026 through December 31, 2027. Eligible Part D members pay a $50 copay for a one-month supply of the Wegovy injection or tablet, after a prior authorization from their prescriber. The copay does not count toward the Part D deductible or out-of-pocket limit.10,11 FitRx does not work with government insurance, so we cannot process Bridge coverage. Medicare.gov/glp1bridge and 1-800-MEDICARE have the eligibility rules.
Your total with FitRx
There are two bills: FitRx membership ($39 the first month, then $135 a month) and the medication, paid at the pharmacy. With covered commercial insurance and the savings offer, the medication can be as little as $25 a month. Without coverage, it is the self-pay price for your dose. HSA and FSA cards are accepted for membership. Ask your plan whether they cover the medication.
NovoCare ships Wegovy to your door. A prescriber still decides whether you should take it.
NovoCare is Novo Nordisk’s pharmacy service. It fills Wegovy prescriptions at the self-pay prices above, which are also available at participating pharmacies, and it delivers to your home for free. It does not prescribe. Novo Nordisk’s site points people toward independent telehealth doctors for that.6
| Question | FitRx | NovoCare |
|---|---|---|
| What is it? | An online membership with licensed providers | Novo Nordisk’s pharmacy service |
| Does it evaluate you and prescribe? | Yes, when a provider finds treatment appropriate | No. It fills prescriptions. |
| Does it sell Wegovy? | No. You pay the pharmacy. | Yes, at self-pay prices |
| Who manages doses and side effects? | Your FitRx provider | Whoever prescribed your Wegovy |
NovoCare details are from Novo Nordisk’s published information as of November 18, 2026.6 Confirm current prices and terms with NovoCare before you fill.
- The $199 price is temporary. It covers a new patient’s first 2 monthly fills of 0.25 mg or 0.5 mg, and the offer ends December 31, 2026.
- Needles are included with the pen.
- A prescription comes first. A licensed clinician has to evaluate you and send one.
That last part is what FitRx does. If you expect to pay cash for brand-name Wegovy, say so during intake and ask your provider whether your prescription can go to NovoCare. The pharmacy is paid for the medication. Your membership pays for the evaluation, dose decisions, side effect support and coaching.
How Wegovy compares with Zepbound, Ozempic and Mounjaro
Four brand names come up most. Two contain semaglutide and two contain tirzepatide. Two are approved for weight management and two are not.
| Medication | Active ingredient | FDA-approved for | Average weight loss in its main trial |
|---|---|---|---|
| Wegovy | Semaglutide | Weight management; cardiovascular risk reduction; MASH (pen) | 14.9% at 68 weeks (2.4 mg pen, adults without diabetes)1 |
| Zepbound | Tirzepatide | Weight management; obstructive sleep apnea with obesity | 20.9% at 72 weeks (15 mg, adults without diabetes)12 |
| Ozempic | Semaglutide | Type 2 diabetes. Not approved for weight loss. | About 6% at 40 weeks (1 mg or 2 mg, adults with type 2 diabetes)13 |
| Mounjaro | Tirzepatide | Type 2 diabetes. Not approved for weight loss. | About 12% at 40 weeks (15 mg, adults with type 2 diabetes)14 |
Each row comes from a different trial with different participants and a different length, so this is not a like-for-like comparison.
One trial did compare the two ingredients directly. SURMOUNT-5 assigned 751 adults with obesity and without diabetes to tirzepatide or semaglutide at the highest dose each person could tolerate. At 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.15
Among these four, only Wegovy has a tablet approved for weight management. It is also approved to lower cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. In the SELECT trial of 17,604 people over about 3 years, major cardiovascular events occurred in 6.5% of people on semaglutide and 8.0% on placebo.16
Wegovy and Ozempic are both semaglutide from Novo Nordisk, but they are not the same prescription. Ozempic is approved for type 2 diabetes at up to 2 mg a week, not for weight loss, while Wegovy’s recommended maintenance dose for weight is 2.4 mg a week.1,13
The bigger average is only one input. Your health conditions, your plan’s coverage and how you tolerate each drug all matter. Our semaglutide and tirzepatide pages go further, and the GLP-1 supply tracker shows current FDA shortage listings.

The FitRx care team
A licensed provider decides whether Wegovy fits you, and in which form
A weekly pen, a daily pill, a different medication or none at all: that is a clinical judgment. At FitRx, a U.S.-licensed physician or nurse practitioner reviews your intake, checks for the conditions and medicines that make semaglutide risky, and decides what to prescribe, if anything.
- U.S.-licensed providers review every intake and make every prescribing decision
- Unlimited secure messaging, plus monthly video or phone visits
- A care coordinator and a coach alongside your provider
- An insurance coordination team for brand-name GLP-1 prior authorizations
This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.
Wegovy FAQs
Is there a Wegovy pill?
Yes. The Wegovy pill is a once-daily semaglutide tablet in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. It is FDA-approved for weight management in adults with obesity, or with overweight and a weight-related condition, and to lower cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.
How do you take the Wegovy pill?
Take one tablet in the morning on an empty stomach with up to 4 ounces of plain water. Swallow it whole, then wait at least 30 minutes before food, drink or other oral medicines. The dose steps up every 30 days: 1.5 mg, 4 mg, 9 mg, then 25 mg.
Is the Wegovy pill as effective as the injection?
They have not been compared in the same trial. People on the 25 mg pill lost an average of 13.6% of their body weight over 64 weeks in OASIS 4. Adults on the 2.4 mg injection lost an average of 14.9% over 68 weeks in STEP 1. Individual results vary.
How much does the Wegovy pill cost?
As of November 18, 2026, Novo Nordisk's self-pay price is $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg, for one bottle of 30 tablets. With commercial insurance that covers Wegovy, the savings offer can lower it to as little as $25 a month. Confirm current prices before you fill.
Can I switch between the Wegovy pill and the pen?
Yes, if your provider agrees. Under the label, the first 25 mg tablet is taken one week after the last 2.4 mg injection. Going the other way, the first 2.4 mg injection is given the day after the last 25 mg tablet.
What are the most common Wegovy side effects?
In adult trials of the 2.4 mg injection: nausea (44% on Wegovy, 16% on placebo), diarrhea (30% and 16%), vomiting (24% and 6%), constipation (24% and 11%) and abdominal pain (20% and 10%). Hair loss was reported by 3%, compared with 1% on placebo.
What is Wegovy HD?
Wegovy HD is the 7.2 mg pen, the maximum weekly dose. The label allows it for adults who have tolerated 2.4 mg for at least 4 weeks when more weight reduction is clinically indicated. In STEP UP, average weight loss at 72 weeks was 18.8% on 7.2 mg and 15.5% on 2.4 mg.
Is there a Wegovy coupon?
Yes: Novo Nordisk's savings offer. With commercial insurance that covers Wegovy, you may pay as little as $25 a month for the pen or the pill. The offer takes off no more than $100 a month, and people with government coverage are excluded. Terms can change, so check before you fill.
How much does Wegovy cost without insurance?
As of November 18, 2026, the self-pay price for the pen is $349 a month for 0.25 mg through 2.4 mg and $399 for Wegovy HD 7.2 mg. New patients pay $199 a month for the first two monthly fills of 0.25 mg or 0.5 mg, through December 31, 2026. The list price is $1,349.02 per package.
Can I use the Wegovy coupon with Medicare or Medicaid?
No. Government beneficiaries are excluded. Separately, the Medicare GLP-1 Bridge lets eligible Part D members get Wegovy for a $50 copay for a one-month supply, from July 1, 2026 through December 31, 2027. FitRx does not work with government insurance and cannot process Bridge coverage.
Can I get Wegovy through NovoCare?
NovoCare is Novo Nordisk's pharmacy service. It fills Wegovy prescriptions and offers free home delivery, but it does not evaluate patients or prescribe. A licensed clinician has to decide Wegovy is appropriate and send the prescription first.
What happens if I stop taking Wegovy?
Weight tends to return. In the STEP 1 extension, participants had lost an average of 17.3% on semaglutide. A year after stopping, they had regained 11.6 percentage points, leaving a net loss of 5.6%. Talk with your provider before stopping.
What should I do if I miss a dose of Wegovy?
Pen: take the missed dose as soon as you can if your next dose is more than 2 days (48 hours) away. Otherwise skip it. After 2 or more missed doses in a row, your prescriber may restart you at a lower dose. Pill: skip the missed tablet and take the next one the following day.
Can I take Wegovy if I am pregnant or planning a pregnancy?
Wegovy may harm an unborn baby. For weight reduction, the label says to stop when pregnancy is recognized and at least 2 months before a planned pregnancy. Breastfeeding is not recommended during treatment with Wegovy tablets. Tell your provider about your plans before you start.
Is Wegovy the same as Ozempic?
Both are semaglutide from Novo Nordisk, but their approvals differ. Wegovy is FDA-approved for weight management, with a recommended maintenance dose of 2.4 mg a week. Ozempic is approved for type 2 diabetes, up to 2 mg a week, and is not approved for weight loss.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality. It is not a generic of Wegovy or Ozempic and was not tested in their trials. A licensed provider decides whether it is appropriate for a patient.
Can I get Wegovy prescribed online?
Yes, if a licensed provider finds it appropriate. For weight management, the label covers adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. A FitRx provider reviews your online intake, typically within 1 to 2 business days. FitRx treats adults 18 and older.
Important safety information for Wegovy
Boxed warning: risk of thyroid C-cell tumors. Semaglutide caused thyroid C-cell tumors in rodents. It is not known whether Wegovy causes these tumors, including medullary thyroid carcinoma (MTC), in people. Do not use Wegovy if you or any member of your family has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
What Wegovy is for. Wegovy (semaglutide) is a prescription medicine used with a reduced-calorie diet and increased physical activity. The injection is used to lower the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce excess body weight and maintain the reduction in adults and pediatric patients 12 and older with obesity, and in adults with overweight and at least one weight-related condition; and to treat noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval). Wegovy tablets are used for the cardiovascular and weight indications in adults only.1
Do not use Wegovy if you have a personal or family history of MTC, if you have MEN 2, or if you have had a serious allergic reaction to semaglutide.
Warnings and precautions. Wegovy can cause:
- Inflammation of the pancreas (acute pancreatitis). A warning sign is severe stomach-area pain that will not go away, with or without vomiting.
- Gallbladder disease. Gallstones were reported in 1.6% of people on the injection (0.7% on placebo) and 2.5% on tablets (1% on placebo).
- Low blood sugar when used with insulin or an insulin secretagogue such as a sulfonylurea.
- Kidney injury when vomiting or diarrhea causes dehydration. Drinking fluids lowers the chance of dehydration.
- Severe stomach and intestinal reactions. It is not recommended for people with severe gastroparesis.
- Allergic reactions, including anaphylaxis and angioedema.
- Complications of diabetic retinopathy in people with type 2 diabetes.
- An increase in heart rate, which your prescriber should monitor.
- Food or liquid entering the lungs during general anesthesia or deep sedation.
A Wegovy FlexTouch pen is for one patient and must never be shared.
Most common side effects (5% or more of people): nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, indigestion, dizziness, abdominal bloating, belching, low blood sugar in people with type 2 diabetes, gas, gastroenteritis, gastroesophageal reflux disease and hair loss.
Pregnancy and breastfeeding. Wegovy may harm an unborn baby. When it is used for weight reduction or cardiovascular risk reduction, stop it when pregnancy is recognized and at least 2 months before a planned pregnancy. Breastfeeding is not recommended during treatment with Wegovy tablets.
Other medicines. Wegovy delays stomach emptying and may affect how medicines taken by mouth are absorbed.
This summary does not replace the full prescribing information or a conversation with your provider.1 Side effects can be reported to the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.
About compounded semaglutide. Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality. It is not a generic of Wegovy or Ozempic, and it has not been studied in their clinical trials.5
See whether the Wegovy pen or the Wegovy pill is an option for you
Complete the online intake. A licensed provider reviews it and tells you what they recommend, and why.
Get startedFitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.
References (16)
- Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. https://pubmed.ncbi.nlm.nih.gov/40961952/
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/36216945/
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Novo Nordisk. NovoCare: Wegovy list price, savings offer and self-pay prices. https://www.novocare.com/patient/medicines/wegovy.html
- Novo Nordisk. Wegovy cost and coverage: what you'll pay for Wegovy. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
- GoodRx. How much does Wegovy cost without insurance? Wegovy prices, coupons and savings. https://www.goodrx.com/wegovy/wegovy-for-weight-loss-cost-coverage
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- Medicare.gov. Weight loss drugs and the Medicare GLP-1 Bridge. https://www.medicare.gov/coverage/weight-loss-drugs
- Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
- Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.